Aurinia Pharmaceuticals Inc. (FRA:IKAP)

Market Cap	1.83B
Revenue (ttm)	226.55M
Net Income (ttm)	66.34M
Shares Out	n/a
EPS (ttm)	0.47
PE Ratio	27.63
Forward PE	18.96
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	8
Open	13.88
Previous Close	14.08
Day's Range	13.88 - 13.88
52-Week Range	6.19 - 14.15
Beta	n/a
RSI	71.02
Earnings Date	Feb 26, 2026

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 130
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: IKAP

Financial Performance

Financial numbers in USD